Researchers across the world are racing to develop preventative approaches and treatment options for COVID-19, including monoclonal antibodies, vaccines and antivirals, as well as investigating the repurposing of existing drugs to treat the infection.
There is no fully approved therapy or vaccine for COVID-19
There are no fully approved treatment options for COVID-19 available yet. Although we have seen a number of Emergency Use Authorisation’s (EUA’s) for certain COVID-19 treatments, like the FDA’s authorisation for Gilead’s remdesivir for example, which was originally used to treat MERS and SARS, which are also coronaviruses (CoV) and are structurally similar to COVID-19.
Neither an effective vaccine nor anti-viral therapeutic agents have been approved to treat COVID-19 or any other human CoV infection till date.
So which R&D programmes have the best chance of success?
Vaccines have the potential to provide long-term protection against the virus, but it could take years before a vaccine against COVID-19 is approved.
Probably the best shot at a reasonably short-term targeted therapy against the COVID-19 epidemic: the possibility of using monoclonal antibodies.
The possibility of using monoclonal antibodies
Monoclonal antibodies can be developed much faster than vaccines, and a lot quicker than a new targeted small-molecule antiviral. Antibodies that specifically block SARS-CoV-2 from attaching to human cells may have great potential.
ETS Nederland can advise on the different R&D programmes for each of these treatment options to ensure rapid development and approval.
Article written by Dr. Henk Tennekes
“I would really enjoy providing expertise on safety tests to achieve fast approval.”
For more information please contact Dr. Henk Tennekes at ETS Nederland B.V.